Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function (Q37140623)

18 August 2017

1 reference

title

Molecular mechanisms that could contribute to prolonged effectiveness of PDE5 inhibitors to improve erectile function (English)

1 reference

18 August 2017

S H Francis

1

1 reference

PubMed ID

18418391

18 August 2017

G Z Morris

series ordinal

2

1 reference

PubMed ID

18418391

18 August 2017

J D Corbin

series ordinal

3

1 reference

18 August 2017

17 April 2008

1 reference

International Journal of Impotence Research

18 August 2017

1 reference

18 August 2017

20

1 reference

18 August 2017

4

1 reference

18 August 2017

333-342

1 reference

https://scigraph.springernature.com/pub.10.1038/ijir.2008.4

18 August 2017

0 references

cites work

Noncholinergic penile erection in mice lacking the gene for endothelial nitric oxide synthase

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

The role of nitric oxide in erectile dysfunction: implications for medical therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

The biology of cyclic GMP-dependent protein kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Cyclic GMP phosphodiesterase-5: target of sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

[3H]sildenafil binding to phosphodiesterase-5 is specific, kinetically heterogeneous, and stimulated by cGMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Phosphodiesterase 5 inhibitors in male sexual dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Phosphodiesterase inhibitors in the treatment of erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Molecular mechanisms and pharmacokinetics of phosphodiesterase-5 antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

PDE5 inhibitors beyond erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Duration of action of sildenafil citrate in men with erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Review of time of onset and duration of clinical efficacy of phosphodiesterase type 5 inhibitors in treatment of erectile dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

The clinical pharmacokinetics of phosphodiesterase-5 inhibitors for erectile dysfunction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Phosphorylation of isolated human phosphodiesterase-5 regulatory domain induces an apparent conformational change and increases cGMP binding affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

A conserved serine juxtaposed to the pseudosubstrate site of type I cGMP-dependent protein kinase contributes strongly to autoinhibition and lower cGMP affinity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

cGMP-dependent protein kinase. Autophosphorylation changes the characteristics of binding site 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Activation by autophosphorylation or cGMP binding produces a similar apparent conformational change in cGMP-dependent protein kinase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Guanosine 3',5'-cyclic monophosphate (cGMP)/cGMP-dependent protein kinase induce interleukin-6 transcription in osteoblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Role of cyclic GMP in gene regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Activation of protein kinase C triggers its ubiquitination and degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

ERK7 expression and kinase activity is regulated by the ubiquitin-proteosome pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Blockade of maitotoxin-induced endothelial cell lysis by glycine and L-alanine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

STa and cGMP stimulate CFTR translocation to the surface of villus enterocytes in rat jejunum and is regulated by protein kinase G

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Stimulation of serotonin transport by the cyclic GMP phosphodiesterase-5 inhibitor sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

On the significance of the retention of ligand by protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Allosteric sites of phosphodiesterase-5 sequester cyclic GMP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

cGMP-dependent protein kinase protects cGMP from hydrolysis by phosphodiesterase-5

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Hepatic sequestration of chlordecone and hexafluoroacetone evaluated by pharmacokinetic modeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Acute toxicity of some perhalogenated acetones

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Overexpression of membrane glycoprotein PC-1 in MDA-MB231 breast cancer cells is associated with inhibition of insulin receptor tyrosine kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Release of glucose from purified galactose-binding protein of Escherichia coli upon addition of galactose.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Mechanisms of NO/cGMP-dependent vasorelaxation

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction.

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Effects of sildenafil on the relaxation of human corpus cavernosum tissue in vitro and on the activities of cyclic nucleotide phosphodiesterase isozymes

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Inhibition of cyclic GMP-binding cyclic GMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Contribution of phosphodiesterase isoenzymes and cyclic nucleotide efflux to the regulation of cyclic GMP levels in aortic smooth muscle cells

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Arginine 75 in the pseudosubstrate sequence of type Ibeta cGMP-dependent protein kinase is critical for autoinhibition, although autophosphorylated serine 63 is outside this sequence

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Autophosphorylation of cGMP‐dependent protein kinase is stimulated only by occupancy of one the two cGMP binding sites

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Toxicokinetics of [14C]hexafluoroacetone in the rat

1 reference

https://api.crossref.org/works/10.1038%2FIJIR.2008.4

7 January 2021

Identifiers

DOI

10.1038/IJIR.2008.4

1 reference

18 August 2017

1 reference

PubMed ID

18418391